Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary MAC Disease
NCT03672630Phase 3Completed
- Sponsor
- Kevin Winthrop
- Start
- Feb 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of rifampicin in Mycobacterium avium complex disease (MAC), sponsored by Kevin Winthrop. Started Feb 2019; status: completed.
02
Drugs
rifampicin
03
Conditions
Mycobacterium avium complex disease (MAC)
Beyond the preview
Go deeper on NCT03672630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672630.